![]() |
|
|
Vol. 292, Issue 1, 319-325, January 2000
Johns Hopkins School of Medicine (K.E.P., S.N.M., B.J.U.),
Baltimore, Maryland; and University of Oklahoma College of Pharmacy
(C.K.B.), Oklahoma City, Oklahoma
The effect of selective tachykinin receptor agonists and antagonists on
human isolated intralobar pulmonary arterial rings was investigated.
Neither Substance P (SP) nor neurokinin A (NKA) contracted the
arteries. Both of these agonists, however, were potent and efficacious
at relaxing the arteries that were precontracted with phenylephrine.
The negative log (M) EC50 values for SP and NKA were 9.0 and 8.3, respectively. The neurokinin (NK)-3 selective agonist,
senktide-analog, and the NK-2 receptor selective agonist, [
-Ala8]NKA(4-10), caused neither contractions nor
relaxations of the arteries, whereas the NK-1 receptor agonist
Ac-[Arg6, Sar9, Met(O2)11]SP(6-11) (ASM-SP) relaxed the tissue with
a potency similar to SP. The relaxations to SP, NKA, and ASM-SP were
competitively antagonized by the selective NK-1 receptor antagonist CP
99994, with a pKb in the nanomolar range.
Antagonism of the ASM-SP-induced relaxations was also noted with FK
888, RP 67580, and L 732,138, although these antagonists were much less
potent than CP 99994 in this regard. Another NK-1 receptor selective
antagonist, SR 140333, caused an insurmountable antagonism of the
SP-induced relaxations. The NK-1 receptor-mediated relaxations could be
blocked by removing the endothelium, or by a combination of
N-nitro-L-arginine and indomethacin.
Measurement of prostanoid generation revealed that in
endothelial-intact but not endothelial-denuded tissue, ASM-SP caused a
selective increase in the production of 6-keto-PGF1
, the stable
metabolite of prostacyclin. The results indicate that stimulation of
NK-1 receptors leads to relaxation of human intralobar pulmonary
arteries, which is mediated largely by nitric oxide and prostacyclin
released from the endothelium of these vessels.
This article has been cited by other articles:
![]() |
A. Hegde, H. Zhang, S. M. Moochhala, and M. Bhatia Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis J. Leukoc. Biol., September 1, 2007; 82(3): 678 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lindstrom, B. von Mentzer, I. Pahlman, I. Ahlstedt, A. Uvebrant, E. Kristensson, R. Martinsson, A. Noven, J. de Verdier, and G. Vauquelin Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1286 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pal, M. J. Nemeth, D. Bodine, J. L. Miller, J. Svaren, S. L. Thein, P. J. Lowry, and E. H. Bresnick Neurokinin-B Transcription in Erythroid Cells: DIRECT ACTIVATION BY THE HEMATOPOIETIC TRANSCRIPTION FACTOR GATA-1 J. Biol. Chem., July 23, 2004; 279(30): 31348 - 31356. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Grubor, R. Ramirez-Romero, J. M. Gallup, T. B. Bailey, and M. R. Ackermann Distribution of Substance P Receptor (Neurokinin-1 Receptor) in Normal Ovine Lung and During the Progression of Bronchopneumonia in Sheep J. Histochem. Cytochem., January 1, 2004; 52(1): 123 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Springer and A. Fischer Substance P-induced pulmonary vascular remodelling in precision cut lung slices Eur. Respir. J., October 1, 2003; 22(4): 596 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Rumsey, D. Aharony, R. A. Bialecki, B. M. Abbott, H. G. Barthlow, R. Caccese, S. Ghanekar, D. Lengel, M. McCarthy, B. Wenrich, et al. Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 307 - 315. [Abstract] [Full Text] |
||||